Belmont Report

The Nuremberg Code (1947) was first, addressing medical experimentation after Nazi atrocities. The Declaration of Helsinki (1964, WMA) extended ethical principles to therapeutic research (earlier codes addressed only non-therapeutic research) and emphasized physician responsibility. The Belmont Report (1979, US federal) systematized ethics into three operational principles and became the basis for US regulatory oversight (IRBs, Common Rule). Helsinki emphasizes physician duty; Belmont emphasizes independent institutional review. Both share core respect for persons, but Belmont's framework is more prescriptive for US-regulated research.

It depends on jurisdiction and data sensitivity. In the US, de-identified data under HIPAA Safe Harbor may be exempt from IRB review. However, Belmont principles still apply if: (1) data are re-identifiable (quasi-identifiers like ZIP code + birth date); (2) consent forms restricted data use (e.g., 'genetic research only'); (3) data concern sensitive topics (mental health, substance abuse) where even de-identified analyses raise justice concerns (findings might stigmatize that population). Best practice: consult your IRB before assuming exemption. At minimum, verify that original data collection satisfied Belmont principles—if original consent violated respect for persons, secondary use doesn't cure it.

These principles can tension in cases like mandatory vaccination or treatment. The Belmont framework resolves this through process: you must truthfully present both the benefits (to the individual and society) and risks, then allow autonomous choice. If a subject refuses a beneficial treatment, respecting that choice is ethically necessary even if you judge it harmful. The exception: imminent danger to others (e.g., untreated TB in vulnerable settings) may justify coercive public health measures, but these require legal authority and subsequent ethical review, not individual researcher discretion.

Belmont principles imply COI considerations (beneficence requires honest risk-benefit assessment; justice requires fair distribution) but do not explicitly mandate COI policies. Modern IRB practice supplements Belmont with COI disclosure and management plans (e.g., researcher with financial interest in drug company must recuse from enrollment decisions, or data must be independently monitored). Document COI and mitigation strategies alongside Belmont principle assessment.

Groups with limited autonomy or susceptibility to exploitation: (1) minors (require parental consent, assent); (2) cognitively impaired persons (require surrogate decision-makers); (3) incarcerated/institutionalized persons (coercive environment; minimize research; special protections); (4) pregnant women/fetuses (additional federal regulations in US); (5) economically disadvantaged (research burden must be justified; incentives must not be coercive); (6) non-English speakers (consent in native language). Vulnerability is context-dependent: a homeless person may be vulnerable in a clinical trial but not when consenting to an interview. Assess vulnerability specific to your study.